Experimental HIV vaccine aims to boost immune control in treated patients
NCT ID NCT06253533
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This early-stage trial tested a therapeutic DNA vaccine called ICVAX in 45 adults with HIV who were already on stable antiretroviral therapy (ART). The goal was to see if the vaccine is safe and can strengthen the body's immune response against HIV. Participants received either the vaccine or a placebo, and researchers monitored side effects and immune cell activity for up to 60 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Third People's Hospital
Shenzhen, Guangdong, 518112, China
Conditions
Explore the condition pages connected to this study.